Olema Pharmaceuticals, Inc. (OLMA)

10.16 +0.21 (+2.11%) 收市：04:00PM EDT

Olema Pharmaceuticals, Inc.

780 Brannan Street
San Francisco, CA 94103
United States
415-651-3316
https://olema.com

版塊: Healthcare
行業: Biotechnology
全職員工: 74

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Sean P. Bohen M.D., Ph.D.	President, CEO & Director	1M	無	1967
Mr. Shane William Charles Kovacs M.B.A.	Chief Operating & Financial Officer	726.17k	無	1974
Dr. Naseem Zojwalla M.D.	Chief Medical Officer	775.48k	無	1973
Mr. Geoffrey Mogilner	Vice President of Investor Relations & Communications	無	無	無
Ms. Julie Dexter	Senior VP & Head of People	無	無	無
Dr. David C. Myles Ph.D.	Chief Discovery & Non-Clinical Development Officer	200k	無	1963
Ms. Demiana Faltaos Ph.D., Pharm.D.	VP & Head of Clinical Pharmacology	無	無	無
Mr. John B. Moriarty Jr., J.D.	Corporate Secretary	434.32k	無	1968
Ms. Sasha Austin CPA	VP of Finance & Controller	無	無	無

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

公司管治

截至 2024年4月1日 止，Olema Pharmaceuticals, Inc. 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中：6；董事會：6；股東權利：8；現金賠償：10。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。